Evidence map›Paper›PMID 40681737›Full record

ArticleDiscover oncology2025

Expression characteristics and biological significance of exosome-related genes in lung cancer.

Qixiang Zhong, Yujie Zhao

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Qixiang ZhongDepartment of Thoracic Surgery, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Yujie ZhaoDepartment of Thyroid and Breast Surgery, Liaoning Maternal and Child Health Hospital, Shenyang, Liaoning, China. zhao_rxwk@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung cancer stands as one of the most prevalent malignancies globally, with its high morbidity and mortality intimately associated with its inconspicuous early symptoms, the advanced stages at diagnosis, and resistance to conventional therapeutic interventions. Exosomes, serving as pivotal mediators of intercellular communication, carry biomolecules that play crucial roles in tumorigenesis, progression, and metastasis, holding promise as novel targets for early diagnosis, prognostic evaluation, and treatment of lung cancer.

methodsIn this study, lung cancer-related datasets were obtained from the GEO database and TCGA. Through differential gene analysis, enrichment analysis, immune infiltration analysis, and drug regulatory analysis, exosome-associated genes pertinent to lung cancer were screened and identified.

resultsThe research revealed significant downregulation of CRYAB, CAV1, HYAL1, and TUBB6 genes in lung cancer tissues, whereas SERINC2, PAICS, SLC2A1, and BIRC5 genes were markedly upregulated. These genes were predominantly enriched in biological processes such as cell migration, oxidative stress response, and cell cycle regulation, as well as in KEGG pathways like the IL-17 signaling pathway. Immune infiltration analysis demonstrated a high correlation between these genes and the infiltration levels of various immune cells. Furthermore, through drug-gene enrichment analysis and molecular docking experiments, significant correlations were found between drugs such as celecoxib and some exosome-related genes, with interaction targets existing between these drugs and CAV1, SLC2A1, and BIRC5 genes.

conclusionThis study unveils the expression characteristics and biological significance of exosome-associated genes in lung cancer. The differential expression of these genes not only offers potential biomarkers for early diagnosis of lung cancer but also lays a foundation for further research into their biological functions in this disease.

Indexed as

Biological functionsDrug regulationExosomesGene expressionImmune infiltrationLung cancer

Identifiers

PMID40681737
PMCPMC12274178

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.